Previous close | 5.83 |
Open | 5.85 |
Bid | 2.10 |
Ask | 6.90 |
Strike | 35.00 |
Expiry date | 2026-01-16 |
Day's range | 4.95 - 5.85 |
Contract range | N/A |
Volume | |
Open interest | 207 |
Q4 2024 Roivant Sciences Ltd Earnings Call
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.